

**Time Table**  
**Day 1, July 19 (Thu)**

			7	8	9	10	11	12	13	14	15	16	17	18	19		
Kobe Portopia Hotel	Room 1 (Portopia Hall)	South Building 1F		Opening Remarks	JS1 Joint Symposium 1 (JCA/JSCO/JSMO) Cancer genomics				President's Special Program Cancer beyond borders: "Any problems on the Border?!" - Crossing all cancer borders for all patients and the world -		SPS Semi-Plenary Session						
	Room 2 (Convention Hall South)	Hall No.2 1F			SY1 Immunotherapy: New Development			MeS-1 The treatment strategy of NSCLC (focused on ICI)	ISY1 New treatment modality for GI cancer		SY2 Diagnosis and treatment strategy for NSCLC with rare driver mutations						
	Room 3 (Hall A)	Hall No.1 2F			SY3 Development of multidisciplinary therapy for esophageal cancer			MeS-2 Impact of primary tumor location on treatment strategy in patients with mCRC	JS2 Joint Symposium 2 (JSPM/JSMO) Integration of oncology and palliative care		SY4 Genomic medicine in the Promotion Plan for the Human Resource Development for Cancer		ES-1 Cancer Associated Thrombosis				
	Room 4 (Hall B)	Hall No.1 2F			O1-1 Colorectal Cancer 1	O1-2 Colorectal Cancer 2		MeS-3 Chemotherapy of HCC for recent and future	O1-3 Immunotherapy 1 (NSCLC 1)	O1-4 Immunotherapy 2 (NSCLC 2)	O1-5 Immunotherapy 3 (NSCLC 3)		ES-2 Regorafenib for metastatic Colorectal Cancer - Up to date-				
	Room 5 (Conference Room 2A)	Hall No.2 2F			O1-6 Hepatoma	JSMO Public Relations Committee Program Non-smoking session		MeS-4 How to choose the right first-line chemotherapy for metastatic colorectal cancer	ISY2 Advance of systemic therapy for hepatocellular carcinoma		SY5 Multidisciplinary treatment for head and neck cancer		ES-3 Cancer immunotherapy in head and neck cancer treatment				
	Room 14 (Conference Room 2B)	Hall No.2 2F						MeS-5 What's the best treatment sequence in recurrent and metastatic HNSCC? -Updated in the new era of Immuno-Oncology-									
	Room 6 (Conference Room 3A)	Hall No.2 3F			SY6 Current status and perspective of treatment for adolescents and young adults with cancer			MeS-6 Exploring a treatment strategy for ALK-NSCLC based on evidence and practice use of ALK inhibitors	JS3 Joint Symposium 3 (JASTRO/JSMO) New treatment strategies using anticancer agents and radiation in the era of Precision medicine		SY7 Immunotherapy & targeted therapy for melanoma & renal cancer: strategic similarity & difference		ES-4 Gastric cancer treatment update - New insights into clinical practice -				
Room 7 (Conference Room 3B)	Hall No.2 3F			O1-7 Basic Research	O1-8 Head and Neck Cancer		MeS-7 About Melanoma treatment (tentative)	O1-9 Gynecologic Cancer	O1-10 Team Medical Care 1	O1-11 Supportive Care 1 (Antiemetic Treatment/Others 1)		ES-5 The role of anti-PD-L1 antibody in immunoncology (the efficacy of avelumab, first anti-PD-L1 antibody in Japan to Merkel cell carcinoma)					
Kobe Portopia Hotel	Room 8 (Kairaku)	Main Building B1F			O1-12 Leukemia	SL1 The BCAA metabolism pathway maintains the stemness of human acute leukemia		MeS-8 Cancer genome profiling test for precision cancer medicine	ISY3 Precision endocrine therapy for advanced/metastatic breast cancer; best choice and best sequence		SY8 Chemotherapy in pregnancy		ES-6 The Evolving Power of Immunotherapy -Transforming Outcomes in Advanced Lung Cancer-				
	Room 9 (Kairaku)	Main Building B1F			AOJS Asia Oceania/JSMO Joint Symposium Investigator initiated clinical trials in Asia, its current issues and future perspectives		MeS-9 Treatment strategy for HER2 positive MBC in EU/Japan	SJS SIOG/JSMO Joint Symposium All oncologists are geriatric oncologists		AJS ASCO/JSMO Joint Symposium Precision medicine: current status and future perspectives		ES-7 Predicting survival outcome and treatment benefit in HR+/HER2-negative metastatic breast cancer					
Kobe International Conference Center	Room 10 (Main Hall)	1F			EL1 New strategy of gynecologic cancer treatment	EL2 Latest update of chemotherapy in lung cancer	EL3 乳がん薬物療法アップデート HER2乳癌治療up to date	EL4 An update on the diagnosis and management of gastroenteropancreatic neuroendocrine tumors	MeS-10 Past and future treatment strategy for EGFR mutation-positive non-small cell lung cancer	EL5 Diagnosis and Treatment for Cancer of Unknown Primary	EL6 Update of Chemotherapy for Head and Neck Cancer and Thyroid Cancer	EL7 A new evidence for the treatment of brain metastases: whole brain radiotherapy vs. stereotactic radiotherapy	EL8 Next-generation therapy for multiple myeloma	EL9 Treatment of Soft Tissue Sarcoma	EL10 The optimal use of Particle therapy (Carbon-ion therapy/Proton beam therapy)	ES-8 The Wonders of PFS/OS (as the Primary endpoint) in Clinical trials	
	Room 11 (International Conference Room)	3F			SY9 Cancer Patients with Delirium : A multidisciplinary approach			MeS-11 What's AYA Patients' issue? From nurse and patient's point of view	SL2 AI Technology for Precision Medicine: Current Status and Future Perspectives (undecided)	MP1 Supporting AYA generation cancer patients; Study through case studies		ES-9 ALK+ Non-Small Cell Lung Cancer -The unsolved issues in Japanese practice-					
	Room 12 (501)	5F			O1-13 Comprehensive Genomic Analyses	O1-14 Lung Cancer 1 (Cytotoxic Drugs 1)		MeS-12 r/r PTCL treatment strategy	O1-15 Lung Cancer 2 (Cytotoxic Drugs 2)	O1-16 Clinical Pharmacology and Therapeutics		ES-10 Great expectations in AML					
	Room 13 (502)	5F			O1-17 Lung Cancer 3 (Biomarker 1 (PD-L1/PD-L2))	O1-18 Lung Cancer 4 (Biomarker 2 (SCLC))		MeS-13 Step One: Medical Treatments for Gastroenteropancreatic Neuroendocrine Tumor	O1-19 Biomarker (Others)	O1-20 Gastric Cancer 1	O1-21 Gastric Cancer 2		ES-11 Precision Medicine for Gastrointestinal Cancer				
	Patient Advocate Program (401+402)	4F						PAP ランチョンセミナー: 日本のがん対策とこれから	President's Special Program (relay)		IPAP どうすれば主治医とうまく話せるの?~伝える力を高めよう~	PAP 患者会活動 A to Z ~みんなが知りたいことを共有しよう~					
Kobe International Exhibition Hall	Poster Area (Convention Hall North)	Hall No.2 1F		8:00-9:00 Poster Set-up	Poster Display							9:00-17:20 Poster Session	17:20-18:10 Poster removal	18:10-18:40			

**Explanatory Notes**

- AOJS =Asia Oceania/JSMO Joint Symposium
- AJS =ASCO/JSMO Joint Symposium
- SJS =SIOG/JSMO Joint Symposium
- SPS =Semi-Plenary Session
- JS =Joint Symposium
- ISY =International Symposium
- SY =Symposium
- EL =Educational Lecture
- SL =Special Lecture
- MeS =Medical Seminar
- MP =Medical Staff Program
- ES =Evening Seminar
- O =Oral
- P =Poster
- (I) Simultaneous Interpretation (E&J)
- (E) English Session
- (S) Sponsored by Princess Takamatsu Cancer Research Fund

Welcome Party  
at 1F, Kobe International Exhibition Hall No.1